John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly,” said John Gillard, CEO of Trinity Biotech. “The two largest CGM ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling ...

We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly,” said John Gillard, CEO of Trinity Biotech. The company plans to complete ...

Shares of Trinity Biotech (NASDAQ:TRIB ... which is projected to exceed $20 billion by 2029,” said John Gillard, CEO of Trinity (TRIB). The company expects to run clinical trials on further ...

Trinity Biotech (TRIB) announced results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring ...